Joshua T. Cohen

Tufts University — United States

Economics, Econometrics and Finance · Social Sciences

50h-index11.1kcitations260works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(102), Pharmaceutical Economics and Policy(38), Healthcare cost, quality, practices(31), Healthcare Policy and Management(29), Economic and Financial Impacts of Cancer(14)

Publications259 total

Communication of Launch Prices by Drug Companies, 2022-2024
The American Journal of Managed Care·2025
Employment Outcomes and Productivity Loss Among Caregivers of Community‐Dwelling Individuals with Alzheimer's Disease
Alzheimer s & Dementia·2025Open Access
Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program
Value in Health·2025
Health utilities in Alzheimer's disease: A survey of patients and caregivers in the United States
Journal of Alzheimer s Disease·2025
Identifying the Influential Dynamic Inputs in Cost-Effectiveness Analyses
Value in Health·2025
US Drug Pricing Patterns Before Loss of Exclusivity
Value in Health·2025· 1 cited
164 An algebra assessment and primer for future clinical and translational scientists entering training
Journal of Clinical and Translational Science·2025Open Access
165 Development of science communication rubrics for trainees in clinical and translational science
Journal of Clinical and Translational Science·2025Open Access
Impact on quality of life, health care access, and health care utilization of individuals with vitiligo: an analysis of the All of Us research program
Archives of Dermatological Research·2024· 4 citedOpen Access
Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia
Journal of the American Geriatrics Society·2024· 6 citedOpen Access
It Is Time to Reconsider the 3% Discount Rate
Value in Health·2024· 18 cited
Are We Valuing Prescription Drugs Appropriately?
Forefront Group·2024· 1 cited
Racial and ethnic differences in lifetime Medicare expenditures for dementia patients
Alzheimer s & Dementia·2023Open Access
The Case For Including Dynamic Drug Pricing In Cost-Effectiveness Analyses Under The IRA
Forefront Group·2023· 2 cited
P18 A Review of HTA Guidelines on Societal and Novel Value Elements
Value in Health·2023Open Access
EE449 Use of Novel and Social Elements of Value in Cost-Effectiveness Analyses
Value in Health·2023Open Access
EE465 Value Estimation of the Diabetes Prevention Program: How Well Does Clinical Trial-Based Cost-Effectiveness Apply to the Real World?
Value in Health·2023Open Access
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
PharmacoEconomics·2023· 2 citedOpen Access
A review of HTA guidelines on societal and novel value elements
International Journal of Technology Assessment in Health Care·2023· 25 citedOpen Access
The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies
Value in Health·2022· 12 cited
page 1 of 13Next →

Frequent Co-authors

Peter J. Neumann(24), David M. Kent(6), David D. Kim(4), Connor We(4), Pei‐Jung Lin(4), John B. Wong(4), D Bellinger(3), Penny M. Kris‐Etherton(3), Rebecca Lawrence(3), David A. Savitz(3), Bennett A. Shaywitz(3), Steven M. Teutsch(3), Gregory C. Gray(3), Howard Fillit(3), Laurel K. Leslie(3), Angie Mae Rodday(3), Teja Thorat(3), Yue Zhong(3), Thomas A Trikalinos(3), Milton C. Weinstein(2)